Clinical trials: Hepatitis C Recurrent
Hepatitis C
Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)
Different immunosuppressive drugs used in transplantation may reduce the body's defences against infection differently. It is known that patients with Hepatitis C virus, known as HCV, who switched from azathioprine to…
- Trial name
- NCT01134952
- Testing
- Mycophenolate to sirolimus switch
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- London Health Sciences Centre
Liver Transplantation, Hepatitis C, Chronic
Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)
This is an exploratory study and is a Phase 3, single-arm, multi-center, open-label study of pegylated interferon alfa-2b, PEG-IFN alpha-2b (PEG-Intron) and ribavirin (RBV) to determine the sustained virologic response (SVR) at…
- Conditions
- Liver Transplantation, Hepatitis C, Chronic, Liver Cirrhosis
- Trial name
- NCT00378599
- Testing
- Combination of (a) pegylated interferon alfa-2b and (b) rebetol
- Volunteers
- 125 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation
The purpose of the study is to evaluate effect of steady-state (when the amount of drug administered (in a given time period is equal to the amount of drug eliminated in that same period) of simeprevir and daclatasvir on the…
- Trial name
- NCT01938625
- Testing
- Simeprevir, Daclatasvir, Ribavirin
- Where
- 6 sites in Germany, Poland and 1 more
- Volunteers
- 35 people
- Sponsor
- Janssen R&D Ireland
Cytomegalovirus Infection, Hepatitis C
Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients
The relationship between cytomegalovirus infection and recurrence of hepatitis C in liver transplant recipients remains controversial.
- Trial name
- VHENUS (NCT01473849)
- Where
- 13 sites in Spain
- Volunteers
- 179 people
- Sponsor
- Sociedad Española de Trasplante Hepático
Renal Insufficiency
Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction
Renal dysfunction in the context of liver transplantation is a major issue, with difficult patients' management and determining a worsened prognosis.
- Trial name
- ATG_HVH (NCT01453218)
- Testing
- ATeGe-Fresenius
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Vall d'Hebron
Hepatitis C Virus Recurrence
Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients
Hepatitis C virus (HCV)-related liver disease is the most common indication for liver transplantation (LT). However, LT does not cure the infection, and therapeutic strategies resulted in very limited efficacy and tolerability in…
- Trial name
- LEG-SIL-LTX-02 (NCT01518933)
- Testing
- Silibinin (Legalon-SIL), Saline
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Rottapharm
Liver Transplantation
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
The study aimed to present our experience in treating recurrent HCV genotype 4 infection post living donor liver transplantation (LDLT) since introduction of the second generation direct acting antiviral drugs (DAAs) in Egypt.
- Trial name
- NCT03133065
- Testing
- treatment of HCV with oral direct acting antiviral therapy
- Volunteers
- 89 people
- Sponsor
- Ain Shams University
Hepatitis C Infection, Viruses
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
The purpose of this study is to test the safety and efficacy of Civacir® to prevent the recurrence of Hepatitis C Virus (HCV) after liver transplant.
- Conditions
- Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human
- Trial name
- NCT01804829
- Testing
- Civacir® 10%
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- Biotest Pharmaceuticals Corporation
Hepatocellular Carcinoma, Hepatitis C Virus Infection
Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
We conducted a randomized controlled trial of adjuvant interferon (IFN) therapy in patients with hepatitis-C virus (HCV)-related cirrhosis who underwent curative resection of hepatocellular carcinoma (HCC) to investigate whether…
- Conditions
- Hepatocellular Carcinoma, Hepatitis C Virus Infection, Liver Cirrhosis, Interferon Treatment
- Trial name
- NCT00273247
- Testing
- Interferon alpha-2b
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute, Milan
Chronic Hepatitis C, Evidence of Liver Transplantation
Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation
In France, 50% of hepatitis C virus carriers develop chronic clinical hepatitis, which may lead to cirrhosis and liver transplantation.
- Trial name
- NCT00375895
- Testing
- ciclosporin
- Where
- 13 sites in France
- Volunteers
- 11 people
- Sponsor
- Rennes University Hospital
Hepatitis C, Cirrhosis
Intravenous Interferon During Liver Transplant
The main goal of this study is to prevent liver allograft infection with Hepatitis C virus in hepatitis C positive patients undergoing liver transplantation.
- Trial name
- NCT01192698
- Testing
- IV interferon
- Volunteers
- 15 people
- Sponsor
- Wake Forest University Health Sciences
Hepatitis C, Chronic
Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings
SHARP-C is an observational cohort study investigating the effect of direct-acting antiviral (DAA) therapy and reinfection in people with chronic hepatitis C virus (HCV) and recent injecting drug use.
- Trial name
- SHARP-C (NCT03343925)
- Where
- 4 sites in Australia
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Hepatitis C, Chronic, Relapse
Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy
The aim of this study is, to compare the relapse rate in chronic HCV patients with genotype 1 or 3 under the combination of standard dose Peg-Interferon alfa-2a (PEG-IFN alfa-2a), Ribavirin (RBV) and Amantadine (AMA) given for 72…
- Trial name
- NCT00299923
- Testing
- Peginterferon alfa-2a, Ribavirin, Amantadine
- Where
- 27 sites in Germany
- Volunteers
- 300 people
- Sponsor
- University of Hamburg-Eppendorf
Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of
HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy
Chronic hepatitis C virus (HCV) infection remains a health burden in people living with human immunodeficiency virus (HIV). Interferon (IFN)-based therapy is the treatment of choice for HCV infection for HIV coinfected patients…
- Conditions
- Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus (HIV) Coinfection
- Trial name
- NCT04768517
- Where
- 7 sites in Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
Cirrhosis, Hepatitis B Infection
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
This phase I trial studies the side effects and the best dose of navitoclax when given together with sorafenib tosylate in treating patients with solid tumors that have returned (relapsed) or do not respond to treatment…
- Conditions
- Cirrhosis, Hepatitis B Infection, Hepatitis C Infection, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT02143401
- Testing
- Laboratory Biomarker Analysis, Navitoclax, Pharmacological Study
- Where
- 10 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Hepatitis C, Chronic
Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C
The purpose of this study is to determine whether lozenges of interferon-alpha that are dissolved in the mouth can prevent relapse in patients with hepatitis C virus infection who had a complete virologic response after receiving…
- Trial name
- NCT00695019
- Testing
- interferon-alpha lozenges
- Where
- 9 sites in Taiwan
- Volunteers
- 169 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Hepatocellular Carcinoma, Hepatitis C, Chronic
Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial
Unexpected results were published in 2016 showed increased aggressiveness and rates of HCC recurrence after curative treatment of HCC in HCV patients treated by DAAs achieving SVR.
- Trial name
- CAUTIOUS (NCT03551444)
- Testing
- Administration of DAA-based treatment
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
Liver Transplantation, Hepatitis C
Treatment of Recurrent Hepatitis C After Liver Transplantation
In France, 50% of the hepatitis C virus carriers develop chronic clinical hepatitis, which may lead to cirrhosis and liver transplantation. Transplant infection by hepatitis C virus is constant after transplantation.
- Trial name
- TRANSPEG (NCT00151580)
- Testing
- Ribavirin
- Where
- 16 sites in France
- Volunteers
- 200 people
- Sponsor
- Rennes University Hospital
Liver Transplantation
Gene Expression in Liver Allograft Rejection and Recurrent Hepatitis C
Acute cellular rejection is relatively common after liver transplantation, typically does not affect graft survival, and is not associated with the development of chronic rejection.
- Trial name
- NCT01428700
- Volunteers
- 275 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatocellular Carcinoma
DAA in the Risk of Recurrence After Curative Treatment of HCC
For early stage of HCC, surgical resection or radiofrequency ablation (RFA) is the mainstay curative treatments. However, recurrence is still a major issue after the surgery or RFA.
- Trial name
- NCT02959359
- Testing
- Ledipasvir 90mg/Sofosbuvir 400 mg, Ribavirin
- Sponsor
- Taipei Veterans General Hospital, Taiwan